Regarding resistance to pyrotinib, a previous study revealed that the P110α inhibitor alpelisib could exert synergistic effects with pyrotinib, reversing resistance in HER2+ BC and providing ideas for overcoming resistance (Chen et al., 2023) (Table 1; Figure 1). Here, ERBB2 is linked to breast cancer.